Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 878 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab in combination with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2019 View  |  Download
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line Atezolizumab (Tecentriq; MPDL3280A) , Paclitaxel (Taxol; paclitaxel albumin) Breast cancer Breast Cancer 2019 View  |  Download
Atezolizumab in addition to cobimetinib and vemurafenib for BRAF mutated metastatic melanoma Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) , Vemurafenib (Zelboraf; PLX4032; R7204; RO5185426; PLX-4032; RG7204) Melanoma Skin Cancer 2019 View  |  Download
Atezolizumab in Addition to Chemotherapy for Stage IV Squamous Non-Small Cell Lung Cancer – First Line Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Atezolizumab in addition to chemotherapy for stage IV non-squamous non-small-cell lung cancer – first line Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Atezolizumab in addition to chemotherapy for small cell lung cancer – first line Atezolizumab (Tecentriq; MPDL3280A) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2018 View  |  Download
Atezolizumab in addition to Carboplatin or Cisplatin and Pemetrexed for Stage IV non-squamous non-small cell lung cancer (NSCLC) Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Cisplatin (Platinol) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Atezolizumab for stage IV non-squamous or squamous non-small cell lung cancer Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Atezolizumab for resected non-small cell lung cancer - adjuvant Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
1 2 81 82 83 84 85 87 88
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications